ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2025

Mar 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2025-03-13

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-13	Common Stock	A	340000	—	Acquired	4113802	Direct
2025-03-13	Common Stock	S	51425	$15.07	Disposed	4062377	Direct

Footnotes

F1: Represents performance awards granted on December 22, 2023, and certified on March 12, 2025, upon the achievement of certain performance goals.

F2: Partial disposition of shares to satisfy tax withholding obligations.

F3: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $14.83 to $15.76, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.